Methylation and acetylation in nervous system development and neurodegenerative disorders

Ageing Research Reviews

Volumn 2, Issue 3, 2003, Pages 329-342

  Mattson, Mark P ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Aging; Alzheimer's disease; Apoptosis; Oxidative stress; Parkinson's disease

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; IRON; METHIONINE; PYRIDOXINE; ROTENONE; DNA;

ACETYLATION; ALZHEIMER DISEASE; APOPTOSIS; COGNITION; CYTOARCHITECTURE; DEGENERATIVE DISEASE; DIET; DNA DAMAGE; DNA METHYLATION; ENZYME DEFICIENCY; EXPERIMENTAL MODEL; GENE EXPRESSION; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; INHERITANCE; METHYLATION; NERVE CELL; NERVE CELL NETWORK; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PLASTICITY; PROTEIN FUNCTION; REVIEW; RISK FACTOR; ANIMAL; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; NERVOUS SYSTEM; PHYSIOLOGY; PRENATAL DEVELOPMENT;

ANIMALIA;

ACETYLATION; ANIMALS; DIET; DNA; DNA DAMAGE; DNA METHYLATION; EMBRYONIC AND FETAL DEVELOPMENT; FOLIC ACID; HOMOCYSTEINE; HUMANS; NERVOUS SYSTEM; NEURODEGENERATIVE DISEASES;

EID: 0347157925     PISSN: 15681637     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1568-1637(03)00013-8     Document Type: Review

References (72)

1. Al-Gazali L.I., Padmanabhan R., Melnyk S., Yi P., Pogribny I.P., Pogribna M., Bakir M., Hamid Z.A., Abdulrazzaq Y., Dawodu A., James S.J. Abnormal folate metabolism and genetic polymorphism of the folate pathway in a child with Down syndrome and neural tube defect. Am. J. Med. Genet. 103:2001;128-132.
2. Bandmann O., Vaughan J.R., Holmans P., Marsden C.D., Wood N.W. Detailed genotyping demonstrates association between the slow acetylator genotype for N-acetyltransferase 2 (NAT2) and familial Parkinson's disease. Mov. Disord. 15:2000;30-35.
3. Betarbet R., Sherer T.B., Greenamyre J.T. Animal models of Parkinson's disease. Bioessays. 24:2002;308-318.
4. Blandini F., Fancellu R., Martignoni E., Mangiagalli A., Pacchetti C., Samuele A., Nappi G. Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease. Clin. Chem. 47:2001;1102-1104.
5. Bottiglieri T., Godfrey P., Flynn T., Carney M.W., Toone B.K., Reynolds E.H. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J. Neurol. Neurosurg. Psychiatry. 53:1990;1096-1098.
6. Cantoni G.L., Mudd S.H., Andreoli V. Affective disorders and S-adenosylmethionine: a new hypothesis. Trends Neurosci. 12:1989;319-324.
7. Chen R.Z., Akbarian S., Tudor M., Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat. Genet. 27:2001;327-331.
8. Cimato T.R., Tang J., Xu Y., Guarnaccia C., Herschman H.R., Pongor S., Aletta J.M. Nerve growth factor-mediated increases in protein methylation occur predominantly at type I arginine methylation sites and involve protein arginine methyltransferase 1. J. Neurosci. Res. 67:2002;435-442.
9. Clarke R., Smith A.D., Jobst K.A., Refsum H., Sutton L., Ueland P.M. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch. Neurol. 55:1998;1449-1455.
10. Costello J.F. DNA methylation in brain development and gliomagenesis. Front Biosci. 8:2003;S175-184.
11. DeKosky S.T., Orgogozo J.M. Alzheimer disease: diagnosis, costs, and dimensions of treatment. Alzheimer Dis. Assoc. Disord. 15. 2001;S3-S7.
12. Duan W., Zhang Z., Gash D.M., Mattson M.P. Participation of prostate apoptosis response-4 in degeneration of dopaminergic neurons in models of Parkinson's disease. Ann. Neurol. 46:1999;587-597.
13. Duan W., Ladenheim B., Cutler R.G., Kruman I.I., Cadet J.L., Mattson M.P. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J. Neurochem. 80:2002;101-110.
14. Endres M., Fan G., Meisel A., Dirnagl U., Jaenisch R. Effects of cerebral ischemia in mice lacking DNA methyltransferase 1 in post-mitotic neurons. NeuroReport. 12:2001;3763-3766.
15. Fan G., Beard C., Chen R.Z., Csankovszki G., Sun Y., Siniaia M., Biniszkiewicz D., Bates B., Lee P.P., Kuhn R., Trumpp A., Poon C., Wilson C.B., Jaenisch R. DNA hypomethylation perturbs the function and survival of CNS neurons in postnatal animals. J. Neurosci. 21:2001;788-797.
16. Farrer L.A., Cupples L.A., Kiely D.K., Conneally P.M., Myers R.H. Inverse relationship between age at onset of Huntington disease and paternal age suggests involvement of genetic imprinting. Am. J. Hum. Genet. 50:1992;528-535.
17. Fekkes, D., van der Cammen, T.J., van Loon, C.P., Verschoor, C., van Harskamp, F., de Koning, I., Schudel, W.J., Pepplinkhuizen, 1998. Abnormal amino acid metabolism in patients with early stage Alzheimer dementia. J. Neural Transm. 105, 287-294.
18. Ferreira A., Caceres A. The expression of acetylated microtubules during axonal and dendritic growth in cerebellar macroneurons which develop in vitro. Dev. Brain Res. 49:1989;205-213.
19. Friedland R.P., Fritsch T., Smyth K.A., Koss E., Lerner A.J., Chen C.H., Petot G.J., Debanne S.M. Patients with Alzheimer's disease have reduced activities in midlife compared with healthy control-group members. Proc. Natl. Acad. Sci. U.S.A. 98:2001;3440-3445.
20. Gasser T. Molecular genetics of Parkinson's disease. Adv. Neurol. 86:2001;23-32.
21. Gearhart D.A., Collins M.A., Lee J.M., Neafsey E.J. Increased beta-carboline 9N-methyltransferase activity in the frontal cortex in Parkinson's disease. Neurobiol. Dis. 7:2000;201-211.
22. Goto K., Numata M., Komura J.I., Ono T., Bestor T.H., Kondo H. Expression of DNA methyltransferase gene in mature and immature neurons as well as proliferating cells in mice. Differentiation. 56:1994;39-44.
23. Gottfries C.G., Lehmann W., Regland B. Early diagnosis of cognitive impairment in the elderly with the focus on Alzheimer's disease. J. Neural Trans. 105:1998;773-786.
24. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging. 18:2001;685-716.
25. Hankey G.J., Eikelboom J.W. Homocysteine and stroke. Curr. Opin. Neurol. 14:2001;95-102.
26. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20:1997;154-159.
27. Hempen B., Brion J.P. Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 55:1996;964-972.
28. Ho L.W., Carmichael J., Swartz J., Wyttenbach A., Rankin J., Rubinsztein D.C. The molecular biology of Huntington's disease. Psychol. Med. 31:2001;3-14.
29. Huang Y., Doherty J.J., Dingledine R. Altered histone acetylation at glutamate receptor 2 and brain-derived neurotrophic factor genes is an early event triggered by status epilepticus. J. Neurosci. 22:2002;8422-8428.
30. Hughes R.E. Polyglutamine disease: acetyltransferases awry. Curr. Biol. 12:2002;R141-R143.
31. Iannello R.C., Crack P.J., de Haan J.B., Kola I. Oxidative stress and neural dysfunction in Down syndrome. J. Neural Transm. Suppl. 57:1999;257-267.
32. Igarashi M., Waki H., Saito S., Komiya Y., Ando S. Characteristics of gangliosides including O-acetylated species in growth cone membranes at several developmental stages in rat forebrain. Dev. Brain Res. 78:1994;17-24.
33. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1:2002;287-299.
34. Keller J.N., Pang Z., Geddes J.W., Begley J.G., Germeyer A., Waeg G., Mattson M.P. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: role of the lipid peroxidation product 4-hydroxynonenal. J. Neurochem. 69:1997;273-284.
35. Kruman I.I., Culmsee C., Chan S., Kruman Y., Guo Z., Penix L., Mattson M.P. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci. 20:2000;6920-6926.
36. Kruman I.I., Kumaravel T.S., Lohani A., Pedersen W.A., Cutler R.G., Kruman Y., Haughey N., Lee J., Evans M., Mattson M.P. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J. Neurosci. 22:2002;1752-1762.
37. Langston J.W. The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology. 47:1996;S153-S160.
38. Lee E.S., Charlton C.G. 1-Methyl-4-phenyl-pyridinium increases S-adenosyl-L-methionine dependent phospholipid methylation. Pharmacol. Biochem. Behav. 70:2001;105-114.
39. Lehmann M., Gottfries C.G., Regland B. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement Geriatr. Cogn. Disord. 10:1999;12-20.
40. Lieberman A.P., Harmison G., Strand A.D., Olson J.M., Fischbeck K.H. Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Hum. Mol. Genet. 11:2002;1967-1976.
41. Marin-Husstege M., Muggironi M., Liu A., Casaccia-Bonnefil P. Histone deacetylase activity is necessary for oligodendrocyte lineage progression. J. Neurosci. 22:2002;10333-10345.
42. 2+ homeostasis and cell death. J Neurosci. 15:1995;6239-6249.
43. Mattson M.P. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol. Rev. 77:1997;1081-1132.
44. Mattson M.P. Establishment and plasticity of neuronal polarity. J. Neurosci. Res. 57:1999;577-589.
45. Mattson M.P. Accomplices to neuronal death. Nature. 415:2002;377-379.
46. Mattson M.P., Partin J., Begley J.G. Amyloid beta-peptide induces apoptosis-related events in synapses and dendrites. Brain Res. 807:1998;167-176.
47. Mattson M.P., Duan W., Lee J., Guo Z. Suppression of brain aging and neurodegenerative disorders by dietary restriction and environmental enrichment: molecular mechanisms. Mech. Ageing Dev. 122:2001;757-778.
48. McCampbell A., Taye A.A., Whitty L., Penney E., Steffan J.S., Fischbeck K.H. Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc. Natl. Acad. Sci. U.S.A. 98:2001;15179-15184.
49. Morales M., Fifkova E. Distribution of acetylated alpha-tublin in brain. In situ localization and biochemical characterization. Cell Tissue Res. 265:2001;415-423.
50. Morrison L.D., Smith D.D., Kish S.J. Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. J. Neurochem. 67:1996;1328-1331.
51. Naoi M., Maruyama W., Niwa T., Nagatsu T. Novel toxins and Parkinson's disease: N-methylation and oxidation as metabolic bioactivation of neurotoxin. J. Neural Transm. Suppl. 41:1994;197-205.
52. O'Donnell W.T., Warren S.T. A decade of molecular studies of fragile X syndrome. Annu. Rev. Neurosci. 25:2002;315-338.
53. Okuse K., Mizuno N., Matsuoka I., Kurihara K. Induction of cholinergic and adrenergic differentiation in N-18 cells by differentiation agents and DNA demethylating agents. Brain Res. 626:1993;225-233.
54. Persky A.M., Brazeau G.A. Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol. Rev. 53:2001;161-176.
55. Pfenninger K.H., Johnson M.P. Nerve growth factor stimulates phospholipid methylation in growing neurites. Proc. Natl. Acad. Sci. U.S.A. 78:1981;7797-7800.
56. Pina B., Martinez P., Suau P. Differential acetylation of core histones in rat cerebral cortex neurons during development and aging. Eur. J. Biochem. 174:1988;311-415.
57. Pogribny I.P., Poirier L.A., James S.J. Differential sensitivity to loss of cytosine methyl groups within the hepatic p53 gene of folate/methyl deficient rats. Carcinogenesis. 16:1995;2863-2867.
58. Salminen A., Tapiola T., Korhonen P., Suuronen T. Neuronal apoptosis induced by histone deacetylase inhibitors. Mol. Brain Res. 61:1998;203-206.
59. Serot J.M., Christman D., Dubost T., Bene M.C., Faure G.C. CSF-folate levels are decreased in late-onset AD patients. J. Neural Transm. 108:2001;93-99.
60. Serra I., Avola R., Condorelli D.F., Surrentino S., Renis M., Kamiyama M., Hashim G.A., Giuffrida A.M. Acetylation and phosphorylation of histones and nonhistone chromosomal proteins in neuronal and glial nuclei purified from cerebral hemispheres of developing rat brain. J. Neurochem. 46:1986;1881-1887.
61. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino R.B., Wilson P.W., Wolf P.A. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 346:2002;476-483.
62. Sieradzan K.A., Mann D.M. The selective vulnerability of nerve cells in Huntington's disease. Neuropathol. Appl. Neurobiol. 27:2001;1-21.
63. Sirotnak F.M., Tolner B. Carrier-mediated membrane transport of folates in mammalian cells. Annu. Rev. Nutr. 19:1999;91-122.
64. Snowdon D.A., Tully C.L., Smith C.D., Riley K.P., Markesbery W.R. Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun study. Am. J. Clin. Nutr. 71:2000;993-998.
65. Takizawa T., Nakashima K., Namihira M., Ochiai W., Uemura A., Yanagisawa M., Fujita N., Nakao M., Taga T. DNA methylation is a critical cell-intrinsic determinant of astrocyte differentiation in the fetal brain. Dev. Cell. 1:2001;749-758.
66. Tucker K.L. Methylated cytosine and the brain: a new base for neuroscience. Neuron. 30:2001;649-652.
67. Vafai S.B., Stock J.B. Protein phosphatase 2A methylation: a link between elevated plasma homocysteine and Alzheimer's disease. FEBS Lett. 518:2002;1-4.
68. Wainfan E., Poirier L.A. Methyl groups in carcinogenesis: effects on DNA methylation and gene expression. Cancer Res. 52:1992;2071S-2077S.
69. Waring R.H., Steventon G.B., Sturman S.G., Heafield M.T., Smith M.C., Williams A.C. S-methylation in motorneuron disease and Parkinson's disease. Lancet. 2:1989;356-357.
70. West R.L., Lee J.M., Maroun L.E. Hypomethylation of the amyloid precursor protein gene in the brain of an Alzheimer's disease patient. J. Mol. Neurosci. 6:1995;141-146.
71. Yankner B.A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron. 16:1996;921-932.
72. Yasui K., Kowa H., Nakaso K., Takeshima T., Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology. 55:2000;437-440.